Abstract
Immune checkpoint inhibitors have emerged as a promising therapeutic option for metastatic cancers. However, they have been associated with inflammatory adverse reactions in various organ systems. A recent article reported a case of sudden bilateral hearing loss that occurred in a patient with metastatic melanoma being treated with pembrolizumab. The authors attributed that complication to an autoimmune reaction secondary to the treatment. This commentary discusses the importance of considering the diagnosis of leptomeningeal metastasis in patients with metastatic melanoma who present with new cranial nerve deficits.
Keywords:
Hearing loss; Immune checkpoint inhibitor; Leptomeningeal metastasis; Melanoma; Pembrolizumab.
MeSH terms
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Diagnosis, Differential
-
Drug-Related Side Effects and Adverse Reactions / diagnosis*
-
Drug-Related Side Effects and Adverse Reactions / immunology
-
Drug-Related Side Effects and Adverse Reactions / pathology
-
Hearing Loss, Sudden / chemically induced
-
Hearing Loss, Sudden / diagnosis*
-
Hearing Loss, Sudden / pathology
-
Humans
-
Melanoma / complications
-
Melanoma / drug therapy*
-
Melanoma / immunology
-
Melanoma / pathology
-
Neoplasm Metastasis
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / immunology
Substances
-
Antibodies, Monoclonal, Humanized
-
Programmed Cell Death 1 Receptor
-
pembrolizumab